<DOC>
	<DOC>NCT02607280</DOC>
	<brief_summary>Investigate the safety and efficacy of DS-5565 in Japanese subjects with Diabetic Peripheral Neuropathic Pain (DPNP) with renal impairment or Post-Herpetic Neuralgia (PHN) with renal impairment.</brief_summary>
	<brief_title>DS-5565 Phase III Study for Renal Impairment in Japanese Subjects</brief_title>
	<detailed_description>The primary objective is the safety and tolerability of DS-5565 in Japanese subjects with moderate to severe renal impairment.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>At screening, creatinine clearance (using the CockcroftGault equation): 1559 mL/min At screening, a pain scale of â‰¥ 40 mm Type 1 or type 2 diabetes mellitus at screening (for patients with diabetic peripheral neuropathic pain DPNP only). Painful distal symmetric polyneuropathy (for patients with DPNP only) postherpetic neuralgia PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening (for patients with PHN only) HbA1c (National Glycohemoglobin Standardization Program) &gt; 10.0% (for patients with DPNP only) Previous use of neurolytic block (for patients with PHN only)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetic peripheral neuropathic pain</keyword>
	<keyword>post-herpetic neuralgia</keyword>
	<keyword>renal impairment</keyword>
</DOC>